CTLA4 and neoplasm: For instance, increased expression of ICOS was observed on CD4+ T cells from peripheral blood and tumor tissues of patients receiving anti-CTLA4 therapy in several types of cancer, including breast cancer, lung cancer, and bladder cancer [27–29].